Urethra cancer

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This early-phase trial is testing whether giving two immunotherapy drugs (durvalumab and tremelimumab) before surgery can help patients with aggressive bladder cancer who cannot take standard chemotherapy. The study involves 54 participants and primarily looks at safety and how t…

This phase II trial tests whether adding cabozantinib to the immunotherapy drug nivolumab can prevent mucosal melanoma from returning after surgery. About 101 patients with resected mucosal melanoma will receive either nivolumab alone or nivolumab plus cabozantinib. The study aim…

This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced or spreading bladder cancer who cannot take standard cisplatin chemo. About 72 adults with recurrent or metastatic urothe…

This early-phase trial is testing a combination of two drugs—erdafitinib and enfortumab vedotin—in 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. Erdafitinib blocks a faulty protein that helps cancer grow, while enfortumab vedotin de…

This phase III trial tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from growing after initial chemotherapy. About 654 patients will receive either the combination or avelumab alone as maintenance therapy. The goal is to s…

This early-phase trial tests a combination of three drugs—bortezomib, gemcitabine, and doxorubicin—in people with advanced urothelial cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the highest safe dose of the two chemotherapy drugs when …

This phase 2 trial is testing whether adding propranolol, a common blood pressure drug, to standard immunotherapy can help control advanced bladder cancer. The study enrolled 6 adults with urothelial carcinoma that has spread or cannot be removed by surgery. Researchers are prima…

This early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…

This phase 2 trial tested a combination of four chemotherapy drugs (5-FU, leucovorin, gemcitabine, and cisplatin) in 46 people with advanced or inoperable adenocarcinoma of the bladder, urethra, or urachus. The goal was to see how many patients' tumors shrank or disappeared. Rese…

This study examines stored tumor samples from 15 people with kidney or bladder cancer who initially responded to immune checkpoint therapy but later developed new tumors. Researchers will compare the genetic and tissue features of the original and new tumors to understand how the…

This small phase II trial is studying whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well patients with advanced bladder cancer respond to the immunotherapy drug nivolumab. Six participants with metastatic urothelial cancer whose tu…